Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$21.24 USD
+0.08 (0.38%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $21.23 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.24 USD
+0.08 (0.38%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $21.23 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Zacks News
Catalyst Pharmaceutical (CPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
Catalyst (CPRX) Up 8.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Corcept (CORT) Up YTD on Robust Korlym Sales, Pipeline Advances
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug
by Zacks Equity Research
ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.
FDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For Review
by Zacks Equity Research
Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.
Here is Why Growth Investors Should Buy Catalyst (CPRX) Now
by Zacks Equity Research
Catalyst (CPRX) possesses solid growth attributes, which could help it handily outperform the market.
Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?
by Zacks Equity Research
Here is how Catalyst Pharmaceutical (CPRX) and DICE Therapeutics, Inc. (DICE) have performed compared to their sector so far this year.
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 5.26% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?
by Zacks Equity Research
On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.
Strength Seen in Alpine Immune Sciences, Inc. (ALPN): Can Its 7.5% Jump Turn into More Strength?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Talaris (TALS) Down on Patient Death From Renal Transplant Study
by Zacks Equity Research
Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.
Zacks Industry Outlook Highlights Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics
by Zacks Equity Research
Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics have been highlighted in this Industry Outlook article.
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
by Zacks Equity Research
RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.
5 Stocks to Bet on in an Innovation-Driven Drug Industry
by Kinjel Shah
Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.
Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?
by Zacks Equity Research
Here is how Catalyst Pharmaceutical (CPRX) and AxoGen (AXGN) have performed compared to their sector so far this year.
Reata (RETA) Up After FDA Scraps AdCom Meeting for NDA Filing
by Zacks Equity Research
The FDA decides not to hold an advisory committee meeting for Reata Pharmaceuticals' (RETA) regulatory filing seeking approval for omaveloxolone in Friedreich's Ataxia.
Moderna (MRNA) Up After Merck Exercises Option for Cancer Jab
by Zacks Equity Research
Merck (MRK) exercises an option to jointly develop and commercialize Moderna's (MRNA) personalized cancer vaccine as part of an existing collaboration agreement between the companies.
United Therapeutics (UTHR) Initiates Tyvaso Study in IPF
by Zacks Equity Research
United Therapeutics (UTHR) initiates a second phase III study evaluating its Tyvaso inhalation solution. The study will be conducted in sites outside the United States and Canada.
Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why
by Zacks Equity Research
Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.
Is Catalyst Pharmaceuticals (CPRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Catalyst Pharmaceutical (CPRX) and IMARA Inc. (IMRA) have performed compared to their sector so far this year.
Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.
Looking for a Growth Stock? 3 Reasons Why Catalyst (CPRX) is a Solid Choice
by Zacks Equity Research
Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.